ICAD Funding: How Much Did They Raise & Key Investors

How Much Did iCAD Raise?
Funding & Key Investors

iCAD, Inc. has solidified its position as a pivotal player in the medical technology sector, securing a cumulative capital infusion of $37.8M. This trajectory of financial backing, punctuated by a recent strategic investment of $12.5M, underscores the market confidence in the company's mission to revolutionize cancer detection through advanced artificial intelligence. By leveraging these resources, iCAD continues to refine its clinical diagnostic capabilities, ensuring that medical providers are equipped with the most precise tools available for early intervention and improved patient outcomes.

The company's history of capital acquisition reflects a disciplined approach to scaling its operations. From its earlier share placements to more recent stock offerings, iCAD has consistently demonstrated the ability to attract institutional support, positioning itself as a leader in the competitive landscape of AI-powered mammography and breast health analytics.

What is iCAD?

iCAD

Software

Healthcare Software

Headquartered in Nashua, New Hampshire, iCAD, Inc. operates at the intersection of oncology and machine learning. The company is best known for its ProFound Breast Health Suite, a comprehensive platform that utilizes proprietary AI algorithms to enhance mammography analysis. By automating the detection of breast cancer, assessing tissue density, and providing risk evaluations, iCAD addresses critical gaps in diagnostic accuracy. Its market position is defined by a commitment to clinical validation, ensuring that its software solutions integrate seamlessly into existing radiology workflows to reduce false positives and improve the efficiency of cancer screening programs globally.

How much funding has iCAD raised?

iCAD has raised a total of $37.8M across 3 funding rounds:

2012

Share Placement

$15M

2019

Stock Offering

$10.3M

2020

Stock Offering

$12.5M

Share Placement (2012): $15M with participation from Deerfield

Stock Issuance/Offering (2019): $10.3M, investors not publicly disclosed

Stock Issuance/Offering (2020): $12.5M, investors not publicly disclosed

Key Investors in iCAD

Deerfield

Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy. The firm supports companies across the healthcare ecosystem with flexible funding models and drives innovation using AI, data, and market research.

What's next for iCAD?

With the support of its recent capital injection, iCAD is poised to accelerate the deployment of its next-generation AI diagnostic tools. The strategic focus will likely center on expanding the clinical utility of its ProFound suite, potentially integrating multi-modal data sources to further refine risk assessment models. As the healthcare industry shifts toward precision medicine, iCAD is well-positioned to capitalize on the growing demand for automated, high-accuracy diagnostic support. Future growth initiatives will likely involve deepening partnerships with major healthcare systems and investing in research and development to maintain its competitive edge in the rapidly evolving field of digital pathology and oncology diagnostics.

See full iCAD company page

See More Financial Insights